Expanded Access for Apixaban

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

NCT05789524 ·Status: TERMINATED ·Phase: PHASE2

The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)

NCT04073498 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

NCT01361126 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Apixaban in Patients With Sickle Cell Disease

NCT02179177 ·Status: TERMINATED ·Phase: PHASE3

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

NCT02246868 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B

NCT06205615 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

NCT03587116 ·Status: COMPLETED ·Phase: PHASE3

PK Driven Prophylaxis for Hemophilia A

NCT02634424 ·Status: TERMINATED ·Phase: NA

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

NCT01496274 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

NCT05568719 ·Status: RECRUITING ·Phase: PHASE3

ADVATE Post Authorization Safety Surveillance

NCT00214734 ·Status: COMPLETED

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00127283 ·Status: COMPLETED ·Phase: PHASE3

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

NCT00168051 ·Status: WITHDRAWN ·Phase: PHASE4

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

NCT07032792 ·Status: RECRUITING ·Phase: PHASE2

Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154

NCT05837338 ·Status: COMPLETED ·Phase: PHASE2

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

NCT01029340 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

NCT04370054 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

NCT01285089 ·Status: COMPLETED

Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B

NCT05360706 ·Status: COMPLETED

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

NCT00571584 ·Status: COMPLETED ·Phase: PHASE4

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

NCT05935358 ·Status: RECRUITING ·Phase: PHASE4

An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

NCT03154437 ·Status: APPROVED_FOR_MARKETING

Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)

NCT04110275 ·Status: UNKNOWN ·Phase: PHASE2

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385 ·Status: WITHDRAWN ·Phase: PHASE4

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

NCT04684940 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2